Nanoparticle-encapsulated Cannabinoid and Temozolomide Combination Therapy for the Treatment of Glioblastoma Multiforme

Glioblastoma multiforme (GBM) (the deadliest form of brain cancer) is associated with poor survival rates (approximately 12-15 months from the time of diagnosis). This is due to the fact that most cases of GBM are resistant to current standards of care. As a result, novel effective treatment options are highly desirable. It has recently been shown that the combination of cannabinoids (such as THC or CBD) with the standard of care chemotherapy agent, temozolomide, demonstrates promise in the treatment of animal models of GBM. The main aim of this project is to design a novel nanoparticle that can deliver a combination of cannabinoids and chemotherapy to GBM tumours.
The proposed project combines 13 years of nanoparticle and drug combination research in the Allen Lab, with Avicanna Inc., a Toronto-based medical cannabis company. TO BE CONT’D

Faculty Supervisor:

Christine Allen

Student:

James Evans

Partner:

Avicanna Inc

Discipline:

Pharmacy / Pharmacology

Sector:

Pharmaceuticals

University:

Program: